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Background: Epigenetic mechanisms may be involved in the regulation of genes found to be differentially
expressed in the visceral adipose tissue (VAT) of severely obese subjects with (MetS+) versus without (MetS-)
metabolic syndrome (MetS). Long interspersed nuclear element 1 (LINE-1) elements DNA methylation levels (%
meth) in blood, a marker of global DNA methylation, have recently been associated with fasting glucose, blood
lipids, heart diseases and stroke.
Aim: To test whether LINE-1%meth levels in VAT are associated with MetS phenotypes and whether they can
predict MetS risk in severely obese individuals.
Methods: DNA was extracted from VAT of 34 men (MetS-: n= 14, MetS+: n= 20) and 152 premenopausal women
(MetS-: n= 84; MetS+: n= 68) undergoing biliopancreatic diversion for the treatment of obesity. LINE-1%meth levels
were assessed by pyrosequencing of sodium bisulfite-treated DNA.
Results: The mean LINE-1%meth in VAT was of 75.8% (SD= 3.0%). Multiple linear regression analyses revealed that
LINE-1%meth was negatively associated with fasting glucose levels (β= -0.04; P= 0.03), diastolic blood pressure (β=
-0.65; P= 0.03) and MetS status (β= -0.04; P= 0.004) after adjustments for the effects of age, sex, waist circumference
(except for MetS status) and smoking. While dividing subjects into quartiles based on their LINE-1%meth (Q1 to Q4:
lower %meth to higher %meth levels), greater risk were observed in the first (Q1: odds ratio (OR) = 4.37, P= 0.004)
and the second (Q2: OR = 4.76, P= 0.002) quartiles compared to Q4 (1.00) when adjusting for age, sex and smoking.
Conclusions: These results suggest that lower global DNA methylation, assessed by LINE-1 repetitive elements
methylation analysis, would be associated with a greater risk for MetS in the presence of obesity.
Keywords: Blood pressure, Epigenetics, Fasting glucose, Global DNA methylation, LINE-1, Metabolic syndrome,
Severe obesity, Visceral adipose tissue* Correspondence: marie-claude.vohl@fsaa.ulaval.ca
1Institute of Nutraceuticals and Functional Foods, 2440 Hochelaga Blvd,
Québec City G1V 0A6, Canada
3Department of Food Sciences and Nutrition, Université Laval, 2425 de
l’Agriculture Av, Québec City G1V 0A6, Canada
Full list of author information is available at the end of the article
© 2012 Turcot et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Turcot et al. Clinical Epigenetics 2012, 4:10 Page 2 of 8
http://www.clinicalepigeneticsjournal.com/content/4/1/10Background
Accumulation of fat preferentially in the abdominal cavity
is frequently associated with clustering of metabolic and
inflammatory alterations, often referred to as metabolic
syndrome (MetS) [1,2]. However, there exists a large het-
erogeneity in the development of these metabolic compli-
cations among obese individuals [3,4], which may partly be
explained by impairment of adipose tissue function [5,6].
Previous studies observed differential gene expression pat-
terns in visceral adipose tissue (VAT) of ‘metabolically
healthy’ vs ‘metabolically unhealthy’ obese individuals [7-9].
It is thus possible that some of these differentially
expressed genes may be functionally related to VAT dys-
function and MetS-related phenotypes. Although poly-
morphisms within several genes have previously been
associated with both gene expression variability and MetS
components [5], epigenetic mechanisms may also contrib-
ute to this variability.
Several epidemiological and animal studies demonstrated
that a detrimental environment during fetal and postnatal
periods, such as maternal obesity and gestational diabetes,
is associated with increased risk of obesity and metabolic
complications later in life [10,11]. These long-term compli-
cations would partly be explained by impaired organogen-
esis and cellular energy metabolism [12], as it may be the
case regarding adipose tissue development and function
[12-14]. Thus, impairments of normal development will ul-
timately change gene expression patterns in key metabolic
pathways involved in obesity and MetS, which may poten-
tially be mediated through epigenetic mechanisms [15,16].
DNA methylation is the most widely studied epigenetic
phenomenon in humans. While association analyses be-
tween CpG methylation levels of candidate genes and com-
plex diseases are increasing [17], an emerging literature
uses CpG methylation of repetitive DNA sequences in dis-
ease association analyses [18]. This is the case for long
interspersed nuclear element 1 (LINE-1) elements, which is
a marker of the global DNA methylation of the genome
[19]. LINE-1 elements are a family of transposon-derived
sequence repeats dispersed in the genome [20]. These re-
petitive elements are normally heavily methylated and their
hypomethylation is commonly associated with cancer de-
velopment and progression [21,22].
Interestingly, recent epidemiological studies also iden-
tified some associations between LINE-1 methylation
variability and ischemic heart disease and stroke [23], as
well as with MetS phenotypes, such as plasma fasting
glucose [24] and plasma lipid levels [24,25].
In view of the recent observations regarding blood
LINE-1 methylation levels and MetS-related phenotypes,
the aim of the present study was to test whether LINE-1
methylation levels in VAT are associated with MetS phe-
notypes and whether they can predict MetS risk in se-
verely obese individuals.Methods
Patient selection
The study subjects were severely obese Caucasian men
(MetS-: n=14; MetS+: n=20) and premenopausal women
(MetS-: n=84; MetS+: n=68) undergoing a biliopancreatic
diversion with sleeve gastrectomy to treat obesity [26] at
the Institut Universitaire de Cardiologie et de Pneumologie
de Québec (Québec City, Canada) from June 2000 to June
2010, and for whom DNA samples from VAT were avail-
able. The study subjects were not taking any medications to
treat MetS features and were not affected by type 2 diabetes
mellitus [27]. Body weight, height, waist circumference,
resting systolic and diastolic blood pressure were measured
using standardized procedures [28]. The day of surgery,
fasting blood samples were drawn into EDTA-containing
tubes and centrifuged for plasma lipid and glucose concen-
tration measurements [28]. VAT from the greater omentum
was sampled during the surgery, as previously reported
[26,29]. The diagnosis of MetS was based on the Inter-
national Diabetes Federation (IDF) definition [30]. MetS+
subjects had to be centrally obese (waist circumference
≥88 cm for women and ≥102 cm for men; USA cut-off
values from the Adult Treatment Panel III [31]) with ≥2
other MetS criteria among the following: fasting plasma
glucose ≥5.6 mmol/l, high-density lipoprotein (HDL)-chol-
esterol <1.29 mmol/l for women and <1.03 mmol/l for
men, triglycerides ≥1.7 mmol/l, systolic blood pressure
(SBP) ≥130 mmHg or diastolic blood pressure (DBP)
≥85 mmHg. All subjects provided a written informed con-
sent to participate in this study, which received the approval
of Université Laval Ethics Committee.
Analysis of LINE-1 CpG methylation in VAT
DNA was extracted from VAT using the DNeasy Blood &
Tissue kit (Qiagen, Mississauga, Ontario, Canada), as
recommended by the manufacturer. DNA extracts were
stored at -80°C until quantitative methylation analysis
using the pyrosequencing technology from Qiagen [32],
which was performed by the McGill University and Gen-
ome Québec Innovation Center Genotyping Platform
team (Montréal, Canada). DNA (1 μg) was treated with
sodium bisulfite followed by a purification step using the
EZ-96 DNA Methylation-Gold kit (Zymo Research, Or-
ange, CA, USA). The polymerase chain reaction (PCR)
was performed in a 25 μl total volume. The final concen-
trations were: 0.05 U/μl for Qiagen HotStarTaq DNA
Polymerase with 1.25×PCR buffer, plus 1.0 mM of mag-
nesium chloride, 0.2 μM for each primer and 0.50 mM for
dNTP mix (Roche NucleoMix). PCR started with an initial
denaturation of 15 minutes at 95°C followed by 45 cycles
of 20 s at 95°C, 30 s at 56°C and 60 s at 72°C; the reaction
finished with 5 minutes at 72°C. PCR products were puri-
fied and sequenced by pyrosequencing as previously
described [33] using 0.3 μM sequencing primer. Primer
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following: forward, 5′-TTT TGA GTT AGG TGT GGG
ATA TA-3′; reverse, 5′-Biotin-AAA ATC AAA AAA TTC
CCT TTC-3′; and sequencing, 5′-AGT TAG GTG TGG
GAT ATA GT-3′. The targeted region comprised three
CpGs located in the 5′ region of LINE-1 elements [19] and
had the following bisulfite-treated DNA sequence: 5′-TTC/
TGTGGTGC/TGTC/TG-3′, where C/T corresponded to
methylated (C) and unmethylated (T) cytosine at each CpG
site. Since the %meth levels of the three CpG sites were
highly correlated between each other (r =0.57 - 0.83, P
<0.0001), the mean %meth of combined LINE-1 CpG sites
was calculated for each subject and used in the association
analyses.Statistical analysis
Non-normally distributed phenotypes were log10 or
negative inverse transformed. The general linear model
(GLM) and the type III sum of squares (all subjects: sex
included in the model; sex-specific: unadjusted) were
used to compare the mean phenotype levels between
subjects without (MetS-) and with (MetS+) MetS. Mul-
tiple linear regression analyses were performed to pre-
dict each MetS-related phenotype and MetS per se while
including LINE-1%meth as an independent variable
along with MetS-related potential confounding factors
(see the Results section for more details about adjust-
ments). After dividing the subjects into quartiles based
on their LINE-1%meth and dichotomized by MetS- and
MetS + groups, a logistic regression analysis was per-
formed to compute odds ratios (ORs) and Wald’s confi-
dence limits to evaluate whether LINE-1%meth quartiles
can predict MetS risk. Finally, a multiple linear regres-
sion analysis was used to predict LINE-1%meth levels
where age, sex and smoking were included in the model
as independent variables. The statistically significant P
value was set at 0.05. Statistical analyses were performed
using SAS software V.9.2 (SAS Institute, Cary, NC,
USA).Results
Characteristics of the study subjects in MetS- and
MetS +groups
The characteristics of the subjects are presented in
Table 1. No difference was observed in the mean age
and smoking frequencies between MetS groups. Study
subjects were severely obese with a mean body mass
index of about 52 kg/m2 and a mean age of about
35 years. Women in the MetS + group had higher mean
body mass index and waist circumference values com-
pared to MetS- women. As expected, all the mean
MetS-related phenotypes differed significantly between
MetS groups.Relationship between LINE-1%meth levels, MetS and its
related phenotypes
The mean LINE-1%meth in VAT of 186 severely obese
subjects was of 75.8% (SD=3.0%) with values ranging from
67.3 to 85.4%. Regression coefficients obtained specifically
for LINE-1%meth in predictive models for each MetS-
related phenotype and MetS per se are shown in Table 2.
Negative associations were seen between LINE-1%meth
levels and fasting glucose levels (β (95% confidence inter-
val) = -0.04 (-0.08 to -0.01); P=0.03) and DBP (-0.65 (-1.26
to -0.05); P=0.03) when age, sex, waist circumference and
smoking were included in the model. LINE-1%meth levels
were also significantly predicting MetS per se (-0.04 (-0.06
to -0.01); P=0.004) when adjusted for age, sex and smok-
ing. Of note, CpG site specific complementary analyses
revealed that methylation levels of the first CpG site inves-
tigated in this assay were more closely related to the previ-
ous MetS phenotypes (fasting glucose: β= -0.04, P=0.007;
DBP: β= -0.52, P=0.04; and MetS per se: β= -0.04,
P=0.0002), and also with the SBP (β= -0.88, P=0.01), as
compared to methylation levels of the second and the third
CpG sites (P >0.05 for the whole model; data not shown).
Prediction of MetS risk using quartiles of LINE-1%meth in
VAT
The study subjects were divided into quartiles (Q) based on
their LINE-1%meth levels (Q1: 67.3% to 73.8%; Q2: 73.8%
to 75.0%; Q3: 75.0% to 77.3%; Q4: 77.3% to 85.4%) and
dichotomized into MetS- and MetS+groups. ORs were
computed to evaluate whether some LINE-1%meth quar-
tiles may be associated with greater risk of MetS, while tak-
ing the higher %meth quartile as the reference group.
Greater risks were observed in the first (OR (95% confi-
dence limits (CL); Q1: OR=4.37 (1.59 to 12.01), P=0.004)
and the second (Q2: OR=4.76 (1.76 to 12.90), P=0.002)
quartiles compared to Q4 (1.00), which was not the case for
the third quartile (Q3: OR=1.82 (0.70 to 4.71), P=0.22)
when adjusting for age, sex and smoking (Table 3). While
using a cut-off point of 75.0% for LINE-1%meth levels, the
sensitivity and specificity of correctly categorizing subjects
as having or not having MetS were 60.2% and 59.2%, re-
spectively. Although the %meth cut-off point that would
confer greater risk for MetS seems slightly different in add-
itional site specific analyses, practically the same observa-
tion could be drawn, that is, quartiles with lower %meth
levels for each CpG site were associated with greater MetS
risk (Q1 for CpG1,2: OR=2.82 to 8.34, P <0.04; Q2 for
CpG1,2: OR=2.80 to 8.16, P <0.04; Q3 for CpG1: OR=
2.71, P=0.047), as compared to the highest %meth quartile
(Q4) (data not shown).
Predictors of LINE-1%meth levels in VAT
The contribution of potential confounding factors in
LINE-1%meth variation was tested using a multiple linear
Table 1 Subject characteristics according to metabolic syndrome (MetS) status
All subjects Men Premenopausal women
Phenotypesa MetS- MetS+ MetS- MetS+ MetS- MetS+
No. of subjects (n) 98 88 14 20 84 68
Smokers (n) 21 (21.4%) 22 (25.6%) 2 (14.3%) 4 (21.1%) 19 (22.6%) 18 (26.9%)
Age (years) 34.9 ± 8.1 35.3 ± 7.3 32.2 ± 8.9 36.8 ± 9.2 35.4 ± 7.9 34.9 ± 6.7
Body Mass Index (kg/m2)b 49.8 ± 8.4 53.8 ± 10.8* 54.5 ± 8.8 56.8 ± 13.1 49.0 ± 8.1 52.9 ± 9.9**
Waist circumference (cm) 130.1 ± 17.0 139.4 ± 19.6** 151.6 ± 15.6 160.7 ± 20.7 126.8 ± 14.7 132.9 ± 14.0*
Fasting glucose (mmol/l) b 4.87 ± 0.39 5.68 ± 0.87*** 5.06 ± 0.33 6.16 ± 0.75*** 4.84 ± 0.39 5.53 ± 0.86***
Triglycerides (mmol/l) b 1.13 ± 0.37 2.20 ± 1.14*** 1.08 ± 0.31 2.42 ± 1.41*** 1.13 ± 0.38 2.13 ± 1.06***
High-density lipoprotein-cholesterol (mmol/l) 1.47 ± 0.26 1.09 ± 0.20*** 1.27 ± 0.17 0.94 ± 0.15*** 1.51 ± 0.38 1.13 ± 0.20***
Systolic blood pressure (mmHg) 130.2 ± 13.4 144.6 ± 17.2*** 132.1 ± 12.8 150.2 ± 19.4** 129.9 ± 13.5 143.0 ± 16.4***
Diastolic blood pressure (mmHg) b 79.9 ± 9.3 90.4 ± 11.9*** 78.8 ± 7.8 89.7 ± 13.2* 80.0 ± 8.7 90.6 ± 11.6***
aData are shown as mean ± SD or n.
bNon-normally distributed phenotypes were transformed for the general linear model analysis: body mass index (negative inverse: -1/(X)), fasting glucose (-1/(X)),
triglycerides (-1/(1 + X)) and diastolic blood pressure (-1/(X)).
*P <0.05, **P <0.01, ***P <0.0001; for differences in mean phenotype levels between MetS- and MetS + groups.
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ance was partly accounted for by sex (β (95% confidence
interval) = -3.21 (-4.27 to -2.15); P <0.0001; lower in
women). Other factors were not significant (age: 0.04 (-0.02
to 0.09), P=0.17; smoking: 0.33 (-0.64 to 1.29), P=0.50).
Discussion
This study revealed that LINE-1%meth levels in VAT were
associated negatively with fasting plasma glucose, blood
pressure and MetS per se using the IDF definition [30].
Subjects situated in the quartiles with lower LINE-1%meth
levels had significantly greater risk to be affected by MetS
when adjusted for age, sex and smoking. Sex was a signifi-
cant predictor of LINE-1%meth levels in VAT of the study
subjects, which was not the case for age and smoking. To
the best of our knowledge, this is the first study analyzing
LINE-1%meth levels in adipose tissue. Most of the pub-
lished studies used peripheral blood cells [18,23,25,36-38],Table 2 Multiple linear regression analysis predicting metabo
LINE-1 methylation level (LINE-1%meth) in the predictive mod
Dependent variables LINE-1%
N
Waist circumference (cm) 180
Fasting glucose (mmol/l) 179
Triglycerides (mmol/l) 179
High-density lipoprotein-cholesterol (mmol/l) 179
Systolic blood pressure (mmHg) 180
Diastolic blood pressure (mmHg) 180
MetS (n) 184
Only coefficients (β), 95% confidence intervals (95% CI) and P values accounted for
coefficient β corresponds to the change in the dependent variable per unit change
constant.
Model A: LINE-1%meth, age, sex and smoking.
Model B: LINE-1%meth, age, sex, smoking and waist circumference.tumorous vs non-tumorous tissues [39,40], and placental
tissues [41] for LINE-1 methylation analysis. LINE-1%
meth levels observed in VAT of the study subjects were
comparable to levels reported in previous epidemiological
studies using white blood cells (WBC) and the same
methylation quantification method [18,23]. It thus sug-
gests that LINE-1%meth levels between VAT and WBC
are comparable, even though the correlation between both
compartments was not tested in the present study. Al-
though further studies would be needed to investigate
whether LINE-1%meth levels in WBC are associated with
MetS risk, as a more convenient biological sample for
clinical and epidemiological purposes, this study under-
lines the presence of DNA methylation heterogeneity in
the VAT of severe obese individuals. This finding supports
the hypothesis of potential epigenetic changes in VAT,
which may contribute to the development of metabolic
perturbations in the presence of abdominal obesity. Sincelic syndrome (MetS)-related phenotypes while including
el
meth
β (95% CI)model P value
-0.51 (-1.33 to 0.32)A 0.23
-0.04 (-0.08 to -0.01)B 0.03
0.01 (-0.04 to 0.06)B 0.64
0.01 (-0.003 to 0.03)B 0.13
-0.71 (-1.55 to 0.13)B 0.10
-0.65 (-1.26 to -0.05)B 0.03
-0.04 (-0.06 to -0.01)A 0.004
by the independent variable LINE-1%meth levels are shown in the table. The
in LINE-1%meth, given that all the other variables in the model remain
Table 3 Logistic regression analysis evaluating the association between LINE-1 methylation level (LINE-1%meth)
quartiles and metabolic syndrome (MetS) risk
LINE-1%meth quartiles MetS-, n=98 MetS+, n=86 Wald’s χ2 = 12.3, P=0.007a, OR (95% CL) P value
Q1: 67.3% to 73.8% 21 (0.22) 25 (0.29) 4.37 (1.59 to 12.02) 0.004
Q2: 73.8% to 75.0% 19 (0.19) 27 (0.31) 4.76 (1.76 to 12.90) 0.002
Q3: 75.0% to 77.3% 28 (0.29) 18 (0.21) 1.82 (0.70 to 4.71) 0.22
Q4: 77.3% to 85.0% 30 (0.31) 16 (0.18) 1.00 -
Odds ratios and P values computed by the logistic regression analysis were obtained while including potential confounding factors in the model, namely age, sex
and smoking. The fourth LINE-1%meth quartile (Q4) was set as the reference group.
aCorresponds to the Wald’s χ2 and P value for the effect of LINE-1%meth quartiles. For the whole model, Wald’s χ2 = 14.0 and P value = 0.03.
CL=Wald’s confidence limits.
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observed in VAT of obese with versus without MetS [7],
gene-specific DNA methylation analysis in VAT are war-
ranted to better understand the contribution of epigenet-
ics in VAT function and, consequently, in obesity-related
metabolic disorders.
The study results showed higher plasma glucose and
DBP levels, along with greater risk for MetS, in presence
of lower LINE-1%meth levels in VAT. However, this rela-
tionship is in the opposite direction of what Pearce et al.
reported [24]. In their samples of 228 Caucasian indivi-
duals aged 49 to 51 years from the Newcastle Thousand
Families Study (Newcastle upon Tyne, UK), they found a
positive association between peripheral blood LINE-1%
meth and fasting glucose levels. They also observed posi-
tive and negative associations, respectively, with plasma
triglyceride and HDL-cholesterol levels after adjustment
for sex [24]. In contrast, Kim et al. reported no signifi-
cant association between blood LINE-1%meth levels and
fasting glucose, triglyceride, HDL-cholesterol, SBP and
DBP in healthy male and female Koreans [42]. Since
their study sample was relatively small (n= 86) and that
no adjustments for sex were performed, it is difficult to
clearly delineate the direction of the relationship be-
tween LINE-1%meth and MetS-related phenotypes.
However, since most studies reported that lower LINE-
1%meth levels in peripheral blood cells were associated
with lower HDL-cholesterol levels [25] and with higher
risk of incident ischemic heart disease and stroke [23], it
is tempting to suggest that lower LINE-1%meth levels
may be associated with MetS and its related phenotypes.
Regarding potential predictors of LINE-1%meth, lower
methylation levels were observed in VAT of women as
compared to men in this study, which was also reported
in several studies using WBC for LINE-1%meth quantifi-
cation [19,38,43,44]. The reason for this sex difference
still remains to be clarified, but it does not appear to be
related to male/female hormone differences [44,45].
While there is growing evidence that WBC global DNA
methylation reduces with aging, several studies did not
observe an association between LINE-1%meth levels
with either age [38,44], or active cigarette smoking inadults [38]. Consistent with these previous studies, age
and smoking were not significant predictors of LINE-1%
meth levels in VAT of the present study subjects.
As reported in a previous study, many genes were dif-
ferentially expressed in VAT of MetS- versus MetS + se-
verely obese men [7] and epigenetic mechanisms have
been postulated as potentially mediating differential
expressions [33]. There is recent evidence supporting a
correlation between LINE-1 and gene-specific %meth
levels, which would depend upon the genomic region
and type of tissue analyzed [46]. However, the nature of
this relationship still remains underexplored. The rele-
vance of LINE-1 methylation quantification as a marker
of global DNA methylation is supported by the fact that
LINE-1 is the most prevalent repetitive sequence in the
human genome (approximately 17% of the genome) [20]
and that about one-third of DNA methylation in the
genome occurs in these elements [35]. Some reports
have also shown that LINE-1%meth levels significantly
correlated with other methods assessing global DNA
methylation, such as genomic 5-methyl cytosine content
[47] and luminometric methylation assay (LUMA) [46].
Bisulfite sequencing of repetitive elements, as performed
here for LINE-1 elements, is a quicker and easier
method to assess global DNA methylation as compared
to genomic 5-methyl cytosine quantification [35]. Thus,
all the above observations would support the utility of
assessing LINE-1%meth as a marker of global DNA
methylation in VAT of our study subjects, and suggest
that the variability observed in LINE-1%meth levels may
be suggestive of concomitant variability in gene-specific
%meth levels potentially associated with differential gene
expression and MetS phenotypes. It should be men-
tioned that methylation quantification of other repetitive
elements, such as Alu repeats, is sometimes performed
to assess global DNA methylation [18], which was not
measured in this study. Correlations between LINE-1
and Alu methylation levels were observed in some but
not all studies [18,48] and may depend on the type of
tissues examined and the responses to cellular stressors
and environmental exposures [18]. LINE-1 and Alu
repeats represent distinct measures of dispersed DNA
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associations observed in this study would be seen with
Alu methylation levels. LINE-1 methylation assessment
was chosen in this study over Alu because of previous
associations between LINE-1 methylation levels and
MetS phenotypes [24,25], as well as with ischemic heart
disease and stroke [23]. Another reason for investigating
LINE-1 elements is its function. There are approximately
3,000 to 5,000 full length (approximately 6 kb) LINE-1
sequences throughout the genome, which comprise the
5′ region targeted in the LINE-1%meth analysis, in
which approximately 60 to 100 elements are still capable
of retrotransposition [49]. It has been postulated in can-
cer that demethylation of LINE-1 elements may increase
their retrotransposable activity, induce genomic instabil-
ity, and deregulate transcriptional activity of specific
genes [50]. Whether such a portrait would also be seen
in other common complex diseases is unknown.
Some study limitations need to be outlined, such as the
possibility of reverse causality [17]. It is indeed possible that
the development of obesity-related metabolic complications
may have induced changes in LINE-1%meth rather than the
reverse. Furthermore, DNA methylation of LINE-1 elements
has been associated with several environmental exposures,
such as air pollution, metal exposures, persistent organic
pollutants, as well as alcohol and dietary folate consumption
(reviewed in [38]). Whether these confounding factors have
influenced LINE-1%meth variability in this study and conse-
quently changed the relationship seen with MetS is un-
known. It may however need some concerns since several
persistent organic pollutants may accumulate in adipose tis-
sue, which have been attributed with obesity development,
type 2 diabetes and related metabolic impairments in human
and animal models [51,52]. Also, VAT is a heterogeneous tis-
sue composed of different cell types, including infiltrated
lymphocytes [53], which are increased in presence of obesity
and associated with insulin resistance [54]. It has been
shown that the percentage of lymphocytes in blood cell
counts was negatively associated with blood LINE-1%meth
levels [18]. Whether our MetS+ subjects have greater
lymphocyte infiltration in their VAT, which may influence
LINE-1%meth values obtained in this study, is a possibility
which warrants further investigation. Finally, Zhang et al.
have previously reported that some variability in LINE-1
methylation levels exist in peripheral leukocytes among
cancer-free individuals of different ethnicities [43]. These
authors proposed that genetic polymorphisms in the folate
metabolism, which provides methyl groups for DNA methy-
lation [55], or other unknown genetic and environmental
factors, may contribute to ethnic differences in global DNA
methylation [43]. It thus suggests that associations observed
among Caucasians in the present study may not necessarily
be generalized to all ethnic groups and may potentially be
influenced by genetic polymorphisms.Conclusions
In summary, this study revealed that lower LINE-1%meth
levels in VAT of non-diabetic severely obese subjects was
associated with higher plasma glucose and DBP levels, and
with a greater risk to be affected by MetS. This investiga-
tion also point out to the necessity to pursue gene-specific
methylation analysis among differentially expressed genes
in the VAT of severely obese subjects MetS- and MetS +
[7] to better understand the involvement of epigenetic
regulation in the development of obesity-related metabolic
complications.
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